Duke Energy Corp vs Mesoblast Limited — how do they compare? Duke Energy Corp trades at $123.14 (market cap $96.05B), while Mesoblast Limited trades at $16.96 (market cap $2.21B). The key difference: Duke Energy Corp is far larger — about 43.5× Mesoblast Limited's market cap, and Duke Energy Corp pays a 3.52% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| DUK | MESO | |
|---|---|---|
Market Cap | $96.05B | $2.21B |
Sector | Utilities | Technology |
52-Week High | $133.46 | $20.96 |
52-Week Low | $113.99 | $12.88 |
Enterprise Value | $188.56B | $2.21B |
Dividend Yield | 3.52% | — |
Signals from Pluang's Aura AI — not financial advice
Duke Energy (DUK) trades at $121.19, down 2.93% on the day, with a bearish technical signal. The company reported strong Q2 2026 earnings of $1.43 per share, beating estimates, and maintains solid fundamentals with a 15.78% net income margin. Recent news highlights operational challenges from storms affecting customers but also strategic initiatives like a $35 million equity units offering and data center growth opportunities.
The outlook is mixed; fundamentals are robust with consistent earnings beats and a healthy dividend, but technical weakness and high debt levels pose risks. Analyst consensus is a 'Hold' with a $136.17 price target, suggesting cautious optimism for long-term investors amid near-term volatility.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Duke Energy is one of the largest U.S. utilities, with regulated utilities in the Carolinas, Indiana, Florida, Ohio, and Kentucky that deliver electricity to nearly 8 million customers. Its natural gas utilities serve more than 1.5 million customers. Duke operates in three major segments: electric utilities and infrastructure
Read more on DUK →Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →